Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | POLM | Q9NP87 | 1/20 | 0.44 |
| ▸ | POLK | Q9UBT6 | 1/20 | 0.44 |
| ▸ | POLL | Q9UGP5 | 1/20 | 0.44 |
| ▸ | POLH | Q9Y253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | DGKA | P23743 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29285072 | 0.98 | POLM (0.46) | KMT2AKDM4EMEN1RECQLPOLM | |
| SCHEMBL9567322 | 0.98 | POLM (0.46) | KMT2AKDM4EMEN1RECQLPOLM | |
| SCHEMBL1756481 | 0.98 | POLM (0.46) | KMT2AKDM4EMEN1RECQLPOLM | |
| SCHEMBL4474985 | 0.98 | POLM (0.46) | KMT2AKDM4EMEN1RECQLPOLM | |
| SCHEMBL4440185 | 0.98 | POLM (0.46) | KMT2AKDM4EMEN1RECQLPOLM | |
| SCHEMBL28128474 | 0.98 | POLM (0.46) | KMT2AKDM4EMEN1RECQLPOLM | |
| SCHEMBL16552524 | 0.95 | KMT2A (0.49) | KMT2AKDM4EMEN1RECQLSMN1; SMN2 | |
| SCHEMBL5342899 | 0.92 | ALDH1A1 (0.49) | KMT2AKDM4EMEN1RECQLSMN1; SMN2 | |
| SCHEMBL8327418 | 0.88 | KMT2A (0.47) | KMT2AKDM4EMEN1RECQLSMN1; SMN2 | |
| SCHEMBL921015 | 0.87 | KMT2A (0.46) | KMT2AKDM4EMEN1RECQLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 299 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024026273-A1 | THERAPY FOR REDUCED OTOTOXICITY FROM CHEMOTHERAPEUTIC AGENT WITH PENTAAZA MACROCYCLIC RING COMPLEX | GALERA LABS, LLC (US) | 2024-02-01 | — | — | WO | claimed |
| US-20230218633-A1 | METHODS OF TREATING ORAL MUCOSITIS | GALERA LABS, LLC | 2023-07-13 | — | — | US | claimed |
| CN-116390731-A | Combined cancer therapy with pentaaza macrocyclic complexes and hormonal therapeutic agents | 加莱拉实验室有限责任公司 | 2023-07-04 | — | — | CN | claimed |
| US-20230158042-A1 | COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT | BIOSSIL INC. (CA) | 2023-05-25 | — | — | US | claimed |
| US-20230149358-A1 | COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT | BIOSSIL INC. (CA) | 2023-05-18 | — | — | US | claimed |
| EP-4157242-A1 | COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT | Galera Labs, LLC (US) | 2023-04-05 | — | — | EP | claimed |
| US-11612608-B2 | Methods of treating oral mucositis | GALERA LABS, LLC (US) | 2023-03-28 | — | — | US | claimed |
| WO-2023009500-A1 | PENTAAZA MACROCYCLIC RING COMPLEX FOR ENHANCED SURGICAL TREATMENT | GALERA LABS, LLC (US) | 2023-02-02 | — | — | WO | claimed |
| US-20220227798-A1 | MANUFACTURE METHOD FOR AQUEOUS FORMULATION OF MANGANESE-CONTAINING COORDINATION COMPLEX, FORMULATION, AND METHOD OF TREATMENT | GALERA LABS, LLC | 2022-07-21 | — | — | US | claimed |
| US-20220118119-A1 | COMBINATION CANCER IMMUNOTHERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX | BIOSSIL INC. (CA) | 2022-04-21 | — | — | US | claimed |
| WO-1997006830-A1 | METHODS OF DIAGNOSTIC IMAGE ANALYSIS USING BIOCONJUGATES OF METAL COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS | MONSANTO COMPANY (US) | 1997-02-27 | — | — | WO | claimed |
| WO-1997006831-A1 | METHODS OF DIAGNOSTIC IMAGE ANALYSIS USING METAL COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS | MONSANTO COMPANY (US) | 1997-02-27 | — | — | WO | claimed |
| EP-0758892-A1 | METHODS OF USE FOR PEROXYNITRITE DECOMPOSITION CATALYSTS, PHARMACEUTICAL COMPOSITIONS THEREFOR | MONSANTO COMPANY (US) | 1997-02-26 | — | — | EP | claimed |
| EP-0756495-A1 | DIAGNOSTIC IMAGE ANALYSIS WITH METAL COMPLEXES | MONSANTO COMPANY (US) | 1997-02-05 | — | — | EP | claimed |
| WO-1996040658-A1 | PROCESS FOR PREPARING SUBSTITUTED POLYAZAMACROCYCLES | MONSANTO COMPANY (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996039396-A1 | MANGANESE OR IRON COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE | MONSANTO COMPANY (US) | 1996-12-12 | — | — | WO | claimed |
| WO-1995031197-A1 | METHODS OF USE FOR PEROXYNITRITE DECOMPOSITION CATALYSTS, PHARMACEUTICAL COMPOSITIONS THEREFOR | MONSANTO COMPANY (US) | 1995-11-23 | — | — | WO | claimed |
| WO-1995028968-A1 | DIAGNOSTIC IMAGE ANALYSIS WITH METAL COMPLEXES | MONSANTO COMPANY (US) | 1995-11-02 | — | — | WO | claimed |
| EP-0679155-A1 | MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE. | MONSANTO CO (US) | 1995-11-02 | — | — | EP | claimed |
| EP-0524161-A1 | Manganese complexes of nitrogen containing macrocyclic ligands effective as catalysts for dismutating superoxide | MONSANTO COMPANY (US) | 1993-01-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158042-A1 | COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT | MC2R, GHRHR, GNRHR | KMT2A 1387/4885KDM4E 3656/4885MEN1 97/4885 |
| US-20230149358-A1 | COMBINATION CANCER THERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX AND HORMONE THERAPY AGENT | HDAC1, HDAC8, SIRT3 | KMT2A 45/4885KDM4E 1919/4885MEN1 1699/4885 |
| US-20220227798-A1 | MANUFACTURE METHOD FOR AQUEOUS FORMULATION OF MANGANESE-CONTAINING COORDINATION COMPLEX, FORMULATION, AND METHOD OF TREATMENT | SOD1, MSH6, SLC30A6 | KMT2A 2524/4885KDM4E 3567/4885MEN1 20/4885 |
| US-20230218633-A1 | METHODS OF TREATING ORAL MUCOSITIS | LPO, SOD3, MPO | KMT2A 3708/4885KDM4E 4300/4885MEN1 4585/4885 |
| US-11612608-B2 | Methods of treating oral mucositis | LPO, SOD3, MPO | KMT2A 3708/4885KDM4E 4300/4885MEN1 4585/4885 |
| US-20220118119-A1 | COMBINATION CANCER IMMUNOTHERAPY WITH PENTAAZA MACROCYCLIC RING COMPLEX | CD274, PDCD1, PDCD1LG2 | KMT2A 706/4885KDM4E 1611/4885MEN1 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.